A difference between the MSC-treated AD-HFD and AD-HFD groups was observed in the eNOS and ELISA assessments of inflammatory markers in CCA and whole blood plasma, demonstrating a positive effect of MSCs (Figure 4). This evidence concerns the gene NOS3 and Alzheimer disease.